Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

Completed · Phase 1

Conditions studied: Hepatitis C

In brief

The purpose of this study is to assess the effect of BMS-791325 on the pharmacokinetics of the CYP3A4 Probe Midazolam.

Key facts

Study ID

NCT00996879

Run by

Bristol-Myers Squibb

People needed

48

Starts

2013-05-01

Expected to finish

2013-09-01

Last updated by the study team

2014-05-06

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female subjects aged 18 to 49 years, with BMI of 18-32 kg/m²
• Women who are not of childbearing potential

You may not qualify if…

• Women of childbearing potential
• Women who are pregnant, breastfeeding, or unwilling or unable to use an acceptable method of birth control.
• Gastrointestinal disease that may impact the absorption of study drug
• History of any chronic respiratory disease (asthma, COPD)

Where it is running

• Wcct Global, Llc — Cypress, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.